|
MYSTIC, Conn. and DUBLIN, Nov. 29, 2010 — Amarin Corporation plc (Nasdaq: AMRN) a clinical-stage biopharmaceutical organization with a focus on cardiovascular disease, these days reported positive, statistically considerable top-line outcomes from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101. The MARINE study, investigating AMR101 as a treatment for quite high triglycerides (≥500 mg/dL), met its primary efficacy endpoints as defined inside the clinical trial protocol and demonstrated a positive safety profile.  The Company believes that AMR101 has the prospective to be the best-in-class product for this indication and that the MARINE study results may support extra patentable claims that could further protect the Company’s rights to this product through 2030.
|
